Interaction between Carbamazepine and Gilteritinib
Major
Metabolism
| ID | DDInter293 and DDInter817 |
| Interaction | Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter. |
| Management | Concomitant use of gilteritinib with combined P-gp and potent CYP450 3A4 inducers should generally be avoided. |
| References | |
| Alternative for Carbamazepine |
N03A
More
|
| Alternative for Gilteritinib |
L01X
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.